Anat Cohen-Dayag Ph.D.
President & CEO
Claimed by owner Compugen
Former names:
Drug Discovery Using Computational Modeling
Public on NASDAQ Aug, 2000
Public on TASE Jan, 2002
Public on TASE Jan, 2002
Compugen
newsbit.us
•
Aug 14, 2022
Compugen changes drug discovery business strategy - News Bit
www.prnewswire.com
•
Aug 8, 2022
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
www.globes.co.il
•
Aug 7, 2022
לא רק חיסכון בהוצאות: קומפיוג'ן מסיימת את ההסכם עם BMS
www.prnewswire.com
•
Mar 21, 2022
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
en.globes.co.il
•
Nov 11, 2021
Bristol Myers Squibb invests $20m in Compugen cancer drug
www.prnewswire.com
•
Jul 15, 2021
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
www.prnewswire.com
•
Jun 29, 2021
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
www.sponser.co.il
•
May 13, 2021
"2021 תהיה שנה חשובה ומרובת אבני דרך עבור קומפיוגן"
www.prnewswire.com
•
May 10, 2021
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
www.prnewswire.com
•
Feb 22, 2021
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
www.firstwordpharma.com
•
Dec 23, 2020
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody P...
www.prnewswire.com
•
Sep 30, 2020
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
www.prnewswire.com
•
Sep 8, 2020
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
www.prnewswire.com
•
Aug 28, 2020
Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
www.prnewswire.com
•
Jun 1, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
en.globes.co.il
•
Mar 12, 2020
Compugen makes equity offering
www.prnewswire.com
•
Mar 9, 2020
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
en.globes.co.il
•
Feb 20, 2020
Compugen expands agreement with BMS
www.prnewswire.com
•
Feb 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
www.prnewswire.com
•
Feb 4, 2020
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
www.prnewswire.com
•
Jan 29, 2020
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
www.prnewswire.com
•
Jan 8, 2020
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
www.prnewswire.com
•
Dec 20, 2019
Compugen Added to the NASDAQ Biotechnology Index
•
Nov 6, 2019
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
www.jpost.com
•
Nov 5, 2019
https://www.jpost.com/HEALTH-SCIENCE/Israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors-606918
www.prnewswire.com
•
Nov 4, 2019
Compugen Announces FDA Clearance of IND Application for COM902
www.prnewswire.com
•
Jul 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
www.prnewswire.com
•
Jul 2, 2019
Compugen Appoints Eran Perry to Its Board of Directors
www.prnewswire.com
•
May 20, 2019
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
www.prnewswire.com
•
Mar 12, 2019
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
en.globes.co.il
•
Feb 26, 2019
Compugen reports revenue, announces restructuring
www.prnewswire.com
•
Jan 22, 2019
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
www.prnewswire.com
•
Jan 14, 2019
Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
en.globes.co.il
•
Oct 11, 2018
BMS invests $12m in Compugen for tumor collaboration
en.globes.co.il
•
Sep 23, 2018
Compugen earns $7.8m payment from Bayer
www.globes.co.il
•
Apr 2, 2018
Compugen signs cancer drug licensing deal worth up to $200m
www.prnewswire.com
•
Aug 7, 2017
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
www.globes.co.il
•
Jan 5, 2015
Compugen reports positive cancer therapy results
www.cgen.com
•
Aug 5, 2013
Publications - Compugen
About
Compugen is a clinical-stage drug-discovery and development company with a broadly applicable predictive-discovery infrastructure that is advancing a therapeutic pipeline consisting mainly of early-stage immuno-oncology programs aimed at harnessing the immune system to eradicate cancer.
The company's pipeline is based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies addressing unmet cancer types and patient populations, both as monotherapies and in combination.
In 2010, Compugen chose to specialize in oncology and immunology, with a focus on immuno-oncology. Compugen's first application of its predictive discovery infrastructure was in the field of immune checkpoints, with the goal of developing novel, effective cancer immunotherapies. The company has also expanded its discovery capabilities to include myeloid target candidates within the tumor microenvironment.
Today, Compugen's pipeline includes multiple opportunities for therapeutics addressing areas of unmet medical need in the field of oncology.
The company's pipeline is based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies addressing unmet cancer types and patient populations, both as monotherapies and in combination.
In 2010, Compugen chose to specialize in oncology and immunology, with a focus on immuno-oncology. Compugen's first application of its predictive discovery infrastructure was in the field of immune checkpoints, with the goal of developing novel, effective cancer immunotherapies. The company has also expanded its discovery capabilities to include myeloid target candidates within the tumor microenvironment.
Today, Compugen's pipeline includes multiple opportunities for therapeutics addressing areas of unmet medical need in the field of oncology.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
Israel, United States, Canada
Funding
Total Funding
$141.92M
Market Cap
$51.38M
Last Funding
$20M
Funding Stage
Total Rounds
7
Investors
4
News
(39)
newsbit.us
•
Aug 14, 2022
Compugen changes drug discovery business strategy - News Bit
www.prnewswire.com
•
Aug 8, 2022
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
www.globes.co.il
•
Aug 7, 2022
לא רק חיסכון בהוצאות: קומפיוג'ן מסיימת את ההסכם עם BMS
www.prnewswire.com
•
Mar 21, 2022
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
en.globes.co.il
•
Nov 11, 2021
Bristol Myers Squibb invests $20m in Compugen cancer drug
www.prnewswire.com
•
Jul 15, 2021
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
www.prnewswire.com
•
Jun 29, 2021
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
www.sponser.co.il
•
May 13, 2021
"2021 תהיה שנה חשובה ומרובת אבני דרך עבור קומפיוגן"
www.prnewswire.com
•
May 10, 2021
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
www.prnewswire.com
•
Feb 22, 2021
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
www.firstwordpharma.com
•
Dec 23, 2020
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody P...
www.prnewswire.com
•
Sep 30, 2020
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
www.prnewswire.com
•
Sep 8, 2020
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
www.prnewswire.com
•
Aug 28, 2020
Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
www.prnewswire.com
•
Jun 1, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
en.globes.co.il
•
Mar 12, 2020
Compugen makes equity offering
www.prnewswire.com
•
Mar 9, 2020
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
en.globes.co.il
•
Feb 20, 2020
Compugen expands agreement with BMS
www.prnewswire.com
•
Feb 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
www.prnewswire.com
•
Feb 4, 2020
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
www.prnewswire.com
•
Jan 29, 2020
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
www.prnewswire.com
•
Jan 8, 2020
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
www.prnewswire.com
•
Dec 20, 2019
Compugen Added to the NASDAQ Biotechnology Index
•
Nov 6, 2019
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
www.jpost.com
•
Nov 5, 2019
https://www.jpost.com/HEALTH-SCIENCE/Israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors-606918
www.prnewswire.com
•
Nov 4, 2019
Compugen Announces FDA Clearance of IND Application for COM902
www.prnewswire.com
•
Jul 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
www.prnewswire.com
•
Jul 2, 2019
Compugen Appoints Eran Perry to Its Board of Directors
www.prnewswire.com
•
May 20, 2019
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
www.prnewswire.com
•
Mar 12, 2019
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
en.globes.co.il
•
Feb 26, 2019
Compugen reports revenue, announces restructuring
www.prnewswire.com
•
Jan 22, 2019
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
www.prnewswire.com
•
Jan 14, 2019
Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
en.globes.co.il
•
Oct 11, 2018
BMS invests $12m in Compugen for tumor collaboration
en.globes.co.il
•
Sep 23, 2018
Compugen earns $7.8m payment from Bayer
www.globes.co.il
•
Apr 2, 2018
Compugen signs cancer drug licensing deal worth up to $200m
www.prnewswire.com
•
Aug 7, 2017
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
www.globes.co.il
•
Jan 5, 2015
Compugen reports positive cancer therapy results
www.cgen.com
•
Aug 5, 2013
Publications - Compugen
The Team
(7)
ACP
AK
Ari Krashin
CFO & COO
HAM
Henry Adewoye, MD
CMO
YTP
Yaron Turpaz, Ph.d
SVP & Senior Advisory, Computational Discovery
OFP
Olivier Froescheis, Ph.d
SVP Corporate & Business Development
ZL
Zurit Levine
Senior Vice President, Technology Innovation
DA
Dorit Amitay
VP HR
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
Undisclosed
Aug 2000
Stock Exchange
NASDAQ
Valuation
Undisclosed
Undisclosed
Public Offering
Undisclosed
Jan 2002
Stock Exchange
TASE
Valuation
Undisclosed
Undisclosed
Private Equity Funding
Post-IPO Equity Funding
$4.92M
Jul 2007
1 Investors
$4.92M
Post-IPO Equity Funding
$30M
Jan 2013
2 Investors
$30M
Post-IPO Equity Funding
$12M
Oct 2018
1 Investors
$12M
Post-IPO Equity Funding
$75M
Mar 2020
$75M
Post-IPO Equity Funding
$20M
Nov 2021
1 Investors
$20M
Media gallery
(1)
Locations
Israel
Harokmim 26, Holon, Israel
Offices Abroad
395 Oyster Point Boulevard, South San Francisco, CA, USA
Locations
Israel
Harokmim 26, Holon, Israel
Offices Abroad
395 Oyster Point Boulevard, South San Francisco, CA, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,